Education
About Us
Working with TipRanks
Follow Us
Chemed (CHE)
:CHE
Earnings Data
Report Date
Apr 29, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
5.55Last Year’s EPS
5.2Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 12.74%
|Next Earnings Date:Apr 29, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strong growth in VITAS with significant challenges in Roto-Rooter revenue decline and Medicare cap management. VITAS's performance was robust, driven by the Covenant Health acquisition and new growth opportunities in Florida, while Roto-Rooter faced revenue declines and operational challenges.Company Guidance
In the Chemed Corporation Fourth Quarter 2024 Earnings Conference Call, management provided guidance indicating that VITAS Healthcare's revenue is expected to increase by 10.5% to 11.3% in 2025, with the average daily census projected to grow by 8.5% to 9%. However, VITAS' adjusted EBITDA margin, before considering the Medicare cap, is forecasted to decrease slightly to a range of 18.4% to 18.9% from 19.1% in 2024. The company anticipates a Medicare cap billing limitation of $9.5 million for 2025. Roto-Rooter is projected to achieve revenue growth of 2.4% to 3%, with an expected EBITDA margin between 25.7% and 26.3%. Overall, the guidance suggests that Chemed anticipates continued growth, albeit with some moderation in margins due to strategic management of Medicare cap implications.Strong VITAS Performance
VITAS reported net revenue of $411 million in Q4 2024, a 17.4% increase year-over-year, with admissions up 3.5% and an average daily census increase of 14.6% compared to the prior year period.
Covenant Health Acquisition Success
The $85 million acquisition of Covenant Health in April 2024 contributed $11 million to $12 million in Q4 revenue, translating to a net income of approximately $2.1 million to $2.3 million.
New Growth Opportunities in Florida
VITAS was awarded a certificate of need in Marion County, Florida, and began operations in Pasco County, highlighting significant growth potential in these regions.
Positive Adjusted EBITDA Growth
Adjusted EBITDA for VITAS excluding Medicare cap increased by 11.8% to $93.2 million, with a margin of 22.5%.
---
CHE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CHE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $545.79 | $586.12 | +7.39% |
| Oct 29, 2024 | $608.70 | $534.83 | -12.14% |
| Jul 24, 2024 | $546.02 | $539.52 | -1.19% |
| Apr 24, 2024 | $615.84 | $571.38 | -7.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Chemed (CHE) report earnings?
Chemed (CHE) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is Chemed (CHE) earnings time?
Chemed (CHE) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHE EPS forecast?
CHE EPS forecast for the fiscal quarter 2025 (Q1) is 5.55.
---